688117 ChengDu Sheng Nuo Biotec
- 28.55
- +0.33+1.17%
ChengDu Sheng Nuo Biotec News
Shengnuo Biotech: Announcement on the extension of some fund-raising investment projects
Basic information on Chengdu Shengnuo Biopharmaceutical Co., Ltd. and financial statements of June 30, 2024
Notice on the company increasing the guarantee amount for wholly-owned subsidiaries to apply for comprehensive bank credit in 2024
Announcement on the postponement of some fund-raising investment projects
Shengnuo Biotech: Announcement on the signing of a major contract for daily operation by a wholly-owned subsidiary
Announcement on the signing of a major contract for daily operation by a wholly-owned subsidiary
Voluntary Disclosure Notice on Signing Overseas “Investment Cooperation Agreements”
Announcement Regarding the Delay of Some Raised Capital Investment Projects
Announcement regarding voluntary disclosure of the approval notice for the listing application of Citric Acid Compound Betavit Manufacture Active Pharmaceutical Ingredient
Basic information and Q1 2024 financial statements of Chengdu Shengnuo Biopharmaceutical Co., Ltd.
Basic information and Q1 financial statements for Chengdu Shengnuoke Peptide Drug Research Co., Ltd. in 2024.
Notice on the company increasing the guarantee amount for wholly-owned subsidiaries to apply for comprehensive bank credit in 2024
Basic information on Chengdu Shengnuo Biopharmaceutical Co., Ltd. and financial statements for the first quarter of 2024
Announcement of Resolutions of the 2023 Annual General Meeting of Shareholders
Legal Opinion of Beijing Hairun Tianrui Law Firm on the 2023 Annual General Meeting of Shareholders of Chengdu Shengnuo Biotechnology Co., Ltd.
2023 Annual General Meeting of Shareholders Meeting Materials
2023 Internal Control Evaluation Report
2024 “Improve Quality, Increase Efficiency, and Focus on Return” Action Plan
Report on the performance of duties of Tianjian Certified Public Accountants (Special General Partnership) by the 2023 Audit Committee
Notice on convening the 2023 Annual General Meeting of Shareholders
Analysis
Price Target
No Data
No Data